Abstract Library

#3021 Homecare Service for Administration of Lanreotide Autogel Injections: Assessment of Patients’ Experience

Introduction: In the past, all Neuroendocrine Neoplasm (NEN) patients (pts) on long-acting somatostatin analogues (SA), had to attend local hospitals/clinics to have them administered by nurses/doctors. Recently, a “homecare service” was developed, allowing pts to have their injections delivered to their home and injections were either administered by themselves, their partner or a Specialist Nurse (SN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Gertner J

Authors: Gertner J, McSweeney A, Furtado O'Mahony L, Quaglia E, John A,

Keywords: homecare,

#3018 Real-Life Data for Telotristat Ethyl in Resistant-to-Treatment Carcinoid Syndrome: Is It Efficacious in Carcinoid Flushing as Well?

Introduction: Results from clinical trials with telotristat ethyl (TE) are really encouraging about its role in carcinoid syndrome-associated diarrhoea, however, its efficacy in flushing has been equivocal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Gertner J

Authors: Gertner J, Eastwood O, Furtado O'Mahony L, Quaglia E, McSweeney A,

Keywords: telotristat,

#2195 Audit of a New Nurse-Led Non-Medical Prescribing (NMP) Clinic for Systemic Anti-Cancer Agents (SACTs)

Introduction: The number of people living with cancer in the UK continues to rise with increased demands on specialist cancer care services. NET incidence and prevalence increases alongside this demand. NETs remain a rare cancer with specialist needs. The clinical nurse specialist (CNS) is ideally placed to support these patients. Oncology clinics are increasingly pressured, the need to think of innovative ways of reducing strain whilst maintaining and enhancing the patients experience is important. To address this we set up a nurse-led SACT NMP clinic alongside the oncology clinic to improve patient experience and reduce oncologist clinic review.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Davies P

Authors: Davies P, Quaglia E, McSweeney A, Caplin M, Thirlwell C,

Keywords: Nurse, Non-Medical Prescribing, SACTs, neuroendocrine, chemotherapy, everolimus, sunitinib,

#1667 A Qualitative Exploration into the Experience of Neuroendocrine Pancreatic Cancer Patients Receiving Molecular Targeted Therapies

Introduction: Despite extensive efficacy date and limited data examining drug related side effects, the patient experience and quality of life data is limited for this patient group

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Quaglia E

Authors: Quaglia E, Uzzell M, Woodcock J, Caplin M,

Keywords: Sunitinib, everolimus,

#1233 CA 19-9: A Novel Role in the Prognosis of Pancreatic Neuroendocrine Tumors

Introduction: Prognostication is difficult for neuroendocrine tumours given their long survival. Staging, grading using Ki67 and receptor status are tools commonly used, but are not without their limitations. CA 19-9 is a tumour marker used in the diagnosis and follow-up of pancreatic adenocarcinomas despite multiple confounding factors, including jaundice. CA 19-9 is not useful in the diagnosis of PNETs having a sensitivity of only 19%, but it is not known whether it has other roles in PNETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Mills L, Ramage J, Quaglia A, Basuroy R, Srirajaskanthan R,

Keywords: CA 19-9,